Acute Kidney Injury in Patients Using SGLT2 Inhibitors: What's the Risk?

Date: 
August, 2017

August 21, 2017. Recently, the U.S. Food and Drug Administration (FDA) issued alerts for 2 sodium-glucose cotransporter-2 (SGLT-2) inhibitors, canagliflozin and dapagliflozin, regarding an increased risk for acute kidney injury (AKI). In response, researchers evaluated data from 2 large health care utilization cohorts to assess the risk of AKI among patients with type 2 diabetes who use SGLT-2 inhibitors in a real-world setting. Researchers compared the incidence of AKI events over a median of 14 months between SGLT-2 inhibitor users and nonusers. Controlling for baseline variables, they found that AKI risk was 60% lower among SGLT-2 users in the first cohort (754 patients: 377 users and 377 nonusers) and 40% lower for SGLT-2 users in the second cohort (2,414 patients: 1,207 users and 1,207 nonusers). Based on these findings, researchers did not identify an increased risk of AKI associated with SGLT2 inhibitor use. You may access the article here.